Don Le

Mr. Don Le

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
JDJason Dayan
Jason Dayan
DLDon Le
Don Le
ASAnzar Sarfraz
Anzar Sarfraz
TTTheodor Di Pauli von Treuheim
Theodor Di Pauli von Treuheim
Farouk J. KhuryFarouk J. Khury
Farouk J. Khury
ADAlan J. Dayan
Alan J. Dayan
Accurate preoperative diagnosis of periprosthetic joint infection (PJI) is difficult, complicating distinction between septic and aseptic failures. This study assessed the value of common serum biomarkers and three calculated ratios—albumin–globulin ratio (AGR), C-reactive protein–albumin ratio (CAR), and C-reactive protein–AGR ratio (CAGR)—in diagnosing PJI after primary total hip arthroplasty (THA). We retrospectively reviewed patients undergoing revision THA for PJI or aseptic failure from 2011 to 2021 at a single institution. Inclusion required reported serum white blood cell count (WBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), albumin (Alb), and total protein (TP). Diagnostic performance was evaluated using areas under the curve (AUCs), with higher values indicating better accuracy. Ratios were defined as: AGR = Alb/[TP − Alb], CAR = CRP/Alb, and CAGR = CRP/AGR. Among 128 cases, 67 were PJI and 61 aseptic. AUCs were: WBC (0.53), CRP (0.69), ESR (0.75), Alb (0.69), Glb (0.63), TP (0.53), AGR (0.72), CAR (0.70), and CAGR (0.71). Optimal cutoff, sensitivity, and specificity were: CRP (10.5, 0.76, 0.59), ESR (41.0, 0.70, 0.72), AGR (1.10, 0.64, 0.75), CAR (3.37, 0.73, 0.64), and CAGR (10.9, 0.75, 0.66). ESR, AGR, CAR, and CAGR demonstrated acceptable accuracy. These readily available markers and ratios may aid PJI diagnosis, supporting improved clinical decision-making.

1 July 2026 in JBJS Reviews
Verified
Journal Article
Closed access
ANAustin Q. Nguyen
Austin Q. Nguyen
ADAndrei Demkov
Andrei Demkov
DLDon Le
Don Le
RVRohan Vemu
Rohan Vemu
MPMark L. Prasarn
Mark L. Prasarn
KSKarim A. Shafi
Karim A. Shafi
» Cervical disk arthroplasty (CDA) is a Food and Drug Administration (FDA)–approved motion-preserving alternative to anterior cervical diskectomy and fusion for 1-level and 2-level degenerative disk diseases, supported by high-level evidence and associated with reduced adjacent segment degeneration and comparable or improved clinical outcomes. » FDA-approved CDA implants differ in biomechanical design, degrees of freedom (DoF), and constraint, affecting motion preservation, segmental control, and long-term kinematics. Devices range from constrained (3 DoF) to semiconstrained and viscoelastic designs (4-6 DoF). Implant articulation and materials impact wear, imaging compatibility, and biomechanical behavior and should be considered during device selection. » Constraint-based classification provides a practical, biomechanics-informed framework for CDA implant selection. Constraint level should be matched to patient pathology. Constrained implants may be preferable in cases of segmental instability, compromised endplate integrity, or poor bone quality. Semiconstrained or viscoelastic devices may offer better outcomes for patients with preserved motion, healthy facets, and high functional demands. » A structured understanding of failure modes is critical for safe and effective CDA use. Complications and failure can result from surgical technique errors (e.g., endplate violation, malposition), biologic response (e.g., osteolysis, heterotopic ossification), or mechanical complications (e.g., implant fracture, subsidence). Technical considerations aid the surgeon in reducing risk of complications.